Almost one third of “critical and major deficiencies” uncovered in the storage and transport of medicines relate to the control and monitoring of temperature, according to the Medicines and Healthcare products Regulatory Agency (MHRA). The Agency reported that problems with temperature accounted for 30 percent of deficiencies, which is more than quality management failures (25 percent), documentation (24 percent), problems with premises or supply (8 percent each) and products (5 percent).
MHRA bases its guidance about storage and transportation on EU guidelines on Good Distribution Practice (GDP), which demand that distributors “ensure that storage conditions are observed at all times, including during transportation”. This not only applies to medicines that need to be stored at low temperatures (cold chain products) but also to medicines that should be stored below 25o or 30oC (temperate chain products). There is also a smaller but growing subset of products that need to be kept at sub-zero temperatures. And it’s not only high temperatures that can present a problem, when products such as vaccines, insulin, biotech products and blood products can all be denatured by freezing.
Following dispatch from a manufacturing facility, the distribution chain for medicines can be complex, potentially involving several storage facilities, wholesalers and modes of transport. Effective systems to measure and record the temperature at which products are held at every stage of their journey are therefore an important feature of systems designed to protect the quality of medicines ultimately administered to patients.